REGiMMUNE Corporation, a privately held biopharmaceutical company
focused on developing technologies and products for immune disorders,
today announced that it has received two separate grants totaling
more than $12 million from the Japan Science and Technology Agency
(JST) and from National Institute of Biomedical Innovation (NIBIO).
Under terms outlined in the five-year grant from JST, REGiMMUNE will
develop its reVax drug for cedar allergy; and the three-year grant
from NIBIO will fund the development of its ToleroVax drug
(RGI-2001), a new immunosuppressant for Graft-versus-Host Disease
(GvHD) associated with stem cell transplantation.
"The substantial funds that REGiMMUNE is receiving from these two
prestigious organizations emphasize the importance of alternative
financing opportunities that are available to us, despite the current
worldwide economic situation," stated Haru Morita, President and Chief
Executive Officer of REGiMMUNE.?  "The financial support from JST and
NIBIO also serves to validate the success of the company’s research
and development capabilities to date, as well as the potential of our
ToleroVax and reVax technologies to produce important new
pharmaceutical products," Mr. Morita continued.
Earlier this year, REGiMMUNE completed an $8 million Series B
financing to advance the company’s compound RGI-2001 for GvHD.?  The
new grants will be used to complete the preclinical programs for the
company’s two lead projects, RGI-1001 for cedar allergy and RGI-2001,
as well as to provide the initial funding for the clinical programs.
About REGiMMUNE
REGiMMUNE is a biotechnology company focused on the discovery,
development and commercialization of immune regulatory therapeutics to
treat life-threatening and debilitating conditions, including
allergies, autoimmune diseases and inflammatory disorders. In addition
to its potential for GvHD, ToleroVax is a therapeutic candidate for
autoimmune diseases such as Multiple Sclerosis (MS) and Systemic
Lupus, in which down-regulation of and/or dysfunction of regulatory
T-cells lead to serious up-regulation of immunity against the
auto-antigen. reVax is the company’s second proprietary technology
platform, which works by modulating the immune system by enhancing
antigen-specific immune regulatory cells. This technique is expected
to be useful in conditions such as Ragweed Allergy, Rheumatoid
Arthritis and MS, where control of an abnormal immune response is
desirable. reVax is being utilized to advance several compounds
through clinical development and eventual commercialization of a broad
range of products for REGiMMUNE and its partners. The company is
headquartered in generic lasix online buy Tokyo, Japan and has a U.S. subsidiary in Mountain
View, California. For more information, visit
About JST
As a nation built on the creativity of science and technology, the
Japanese Science and Technology Agency was established as a core
organization for implementing Japan’s science and technology policy
in line with the objectives of the Science and Technology Basic Plan.
For more information, visit
About NIBIO
Established in April 2005, with the Osaka branch of National
Institute of Health Sciences as the nucleus and integrating aspects
of the National Institute of Infectious Diseases and the
Pharmaceuticals and Medical Devices Agency, NIBIO is an independent
administrative agency facilitating new pharmaceutical and medical
device development by supporting research and development at private
corporations and universities. For more information, visit

NIBIO
Buy diflucan pills | generic soma online buy | generic acomplia online buy